Dyslipidaemia among renal transplant recipients: Cyclosporine versus tacrolimus

Journal of the Pakistan Medical Association

Volumn 64, Issue 5, 2014, Pages 496-499

  Fazal, Muhammad Asim ^a   Idrees, Muhammad Khalid ^a   Akhtar, Syed Fazal ^a  

^a SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

Author keywords

Cyclosporine; Dyslipidaemia; Lipid; Renal transplant; Tacrolimus

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CREATININE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; TACROLIMUS; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; RANDOMIZED CONTROLLED TRIAL;

ADULT; CYCLOSPORINE; DYSLIPIDEMIAS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; TACROLIMUS; YOUNG ADULT;

EID: 84899643272     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Collins AJ, Foley RN, Gilberts, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. CJASN 2009; 4: S5-11
2. Kahan BD. Cyclosporin. N Engl J Med 1998; 321: 1725-38
3. Neipp M, Behya K, Jackobs S, Vilsendorf AM, Richter N, Becker T, et al. Quality of life in adult transplant recipients more than 15 years after kidney transplantation. Transplantation 2006; 81: 1640-4
4. Spinelli GA, Felipe CR, Park SI, Mandia-Sampaio EL, Tedesco-Silva H Jr, Medina-Pestana JO. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen. Transplant Proc 2011; 43: 3730-7
5. Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2009; 15: CD005019
6. Ojha JP. Management of dyslipidemia in CKD, dialysis and renal transplant recipient. Clinical Queries: Nephrology 2012; 1: 191-7
7. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation (Serial online) 2011 (Cited 2013 Jan 17). Available from URL: http://www.srtr.org/annual_reports/2010/flash/01_kidney/index.html#/16/zoomed
8. Rizvi SA, Naqvi SA, Zafar MN, Hussain Z, Hashmi A, Hussain M, et al. Living related renal transplants with lifelong follow-up. A model for the developing world. Clin Nephrol 2010; 74: S142-9
9. Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005; 20: 968-73
10. Dumler F, Kilates C. Metabolic and nutritional complications of renal transplantation. J Ren Nutr 2007; 17: 97-102
11. Younas N, Wu CM, Shapiro R, McCauley J, Johnston J, Tan H, et al. HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival. BMC Nephrology 2010; 11: 5
12. Pourmand G, Saraj A, Dehgani S, Mehrsai AR, Nikoobakht MR, Talibnajad M, et al. should post kidney transplantation hyperlipidemia considered a risk factor for graft function? Int J Org transplant Med 2010; 1: 131-7
13. Rabbat CG, Thorpe KE, Russell JD, Churchill DN. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000; 11: 917-22
14. Prakash J, Ghosh B, Singh S, Soni A, Rathore SS. Causes of death in renal transplant recipients with functioning allograft. Ind J Nephrol 2012; 22: 264-8
15. Ligtenberg G, Hené RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368-73
16. Razeghi E, Shafipour M, Ashraf H, Pourmand G. Lipid disturbances before and after renal transplant. Exp Clin Transplant 2011; 9: 230-5
17. Kanbay M, Yildirir A, Akcay A, Colak T, Ozdemir FN, Muderrisoglu H. Effects of immunosuppressive drugs on serum lipid levels in renal transplant recipients. Transplant Proc 2006; 38: 502-5
18. Ghnaimat M, Nsour W, Abbadi R. The effect of immunosuppressive agents on lipid profile of post renal transplant patients. JRMS 2006; 13: 10-3
19. Ghisdal L, Bouchta NB, Broeders N, Crenier L, Hoang AD, Abramowicz D, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008; 21: 146-51
20. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Nikiteas N, Kostakis A. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol 2008; 40: 521-7
21. Mohammad HF, Al-Shamma K, Al-Hassani N. Evaluation of immunosuppressive regimens in kidney transplanted patients in Iraq. Global J Med Res 2012; 12: 5-20
22. Ciftci HS, Ayna TK, Caliskan YK, Turkmen A, Gurtekin M. Lipid parameters, doses and blood levels of calcineurin inhibitors in renal transplant patients. Ind J Clin Biochem 2012; 28: 164-8
23. Rostaing L, Sánchez-Fructuoso A, Franco A, Glyda M, Kuypers DR, Jaray J. Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: a multicenter study. Transpl Int 2012; 25: 391-400
24. Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant 2012; 27: 850-7
25. Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010; 23: 133-42